Glaucoma Subspecialty Day 2017
    Glaucoma, Medical Therapy

    Drs. Joel Schuman and Fabio Lavinsky discuss novel IOP-lowering agents, which include Rho-associated protein kinase (ROCK) inhibitors (netarsudil), nitric oxide–donating prostaglandin analogs (latanoprostene bunod), and adenosine receptor agonists. In addition, they discuss drugs with targets other than IOP reduction, such as neuroprotective agents, optic nerve–regenerating agents, gene therapy, and stem cell-based therapies.